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Abstract: 
In the last years, researchers have shown how stress is strictly involved in the onset and development of 
depression, principal due to the mechanism of dysregulation of the Hypothalamic-pituitary-adrenal axis. 
Stressful experiences during the prenatal period or during the first years of life can affect the brain 
developmental trajectories leading to an enhanced vulnerability of developing several psychiatric and 
neurodevelopmental disorders later in life, but not all the subjects exposed to stressful experiences suffer 
from such illnesses . For this reason, during the last decades, researchers have focused their attention on the 
identification of stress coping mechanisms, able to explain the resilience or vulnerability of developing 
psychiatric diseases, such as depression. 
MiRNAs represent one of the epigenetic mechanisms associated with long-lasting detrimental effects of 
stress and they have been proposed as possible biomarkers able to identify subjects at high risk to develop 
depression and to predict the treatment response.  
The focus of this review is to evaluate the current state of the art related to the relationship between 
miRNAs, stress vulnerability and depression by discussing, both in rodents as well as in humans, how 
miRNAs can mediate the long-lasting effect of stress and how changes in miRNAs expression can also be 
involved in the response to pharmacological treatments. 
To this purpose, different combinations of relevant keywords were used to search references  in PubMed 
database. 
Studies, both in humans and in animals show several clues that give an idea of the possible mediation of 
epigenetic mechanisms in the vulnerability and/or resilience related to the pathology. For this reason, the 
evaluation of miRNAs expression in peripheral blood and tissues might be a promising breakthrough in the 
diagnosis and prevention of depression and in the identification of novel targets for preventive 
pharmacological or non-pharmacological strategies. 
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1. Stress, Depression and miRNAs 
It is well known that adverse experiences during the prenatal period or during the first years of life can affect 
the brain developmental trajectories leading to an enhanced vulnerability of developing several psychiatric 
and neurodevelopmental disorders later in life (Lockhart et al. 2018). Indeed, early life stressful experiences 
represent an important clinical risk factor for the future development of altered behaviours and psychiatric 
disorders (Cirulli et al. 2009; Fryers and Brugha 2013; Syed and Nemeroff 2017). However, the molecular 
mechanisms underlying the long-lasting effects of stress are poorly understood, and likely interact with 
genetic and biological factors throughout the lifespan, a mechanism also known as gene X environment 
interaction (McEwen 2012; Holmes and Singewald 2013; Karatsoreos et al. 2013). In this context, epigenetic 
mechanisms, such as DNA methylation and microRNAs (miRNAs), have been widely described to mediate 
the effect of these stressful experiences and to be involved in the vulnerability of depression (Serafini et al. 
2014; Januar et al. 2015) as well as for other stress-related mental disorders (Klengel and Binder 2015; 
Nestler et al. 2016). Indeed, they act by inducing long-lasting alterations in the expression of key genes and 
pathways (Menke 2014), that in turn may contribute to the development of the pathology.  
MiRNAs, as mentioned before, represent together with DNA methylation, one of the epigenetic mechanisms 
associated with the long-lasting detrimental effects of stress. MiRNAs are small non-coding RNA molecules 
(21-24 nucleotides), recognized as one of the fundamental factors involved in the post-transcriptional 
regulation of gene expression. Indeed, it has been estimated that they are able to modulate up to 60% of 
protein-coding genes in humans (Catalanotto et al. 2016), generally repressing the expression of their target 
mRNAs (Bushati and Cohen 2007; Friedman et al. 2009; Rao et al. 2013). The fine-tuning of gene 
expression by miRNAs is usually regulated through the binding to the 3'UTR of mRNA, leading to mRNA 
degradation or translational repression (Bartel 2004). Also coding domain sequence and 5’UTR are targeted 
by miRNAs with consequent regulatory effects on gene expression (Brummer and Hausser 2014; Catalanotto 
et al. 2016). Because of their ubiquitous role in gene regulation, they are involved in many physiological 
processes, such as cell proliferation, differentiation, apoptosis and development. A dysregulation in the 
miRNAs’ machinery has been related to several pathological conditions, including neuropsychiatric and 
neurodevelopmental disorders (Ha 2011; Xu et al. 2012; Maffioletti et al. 2014).  
MiRNAs have been proposed as non-invasive candidate biomarkers that would allow the early identification 
of individuals at high-risk of developing depression and of those subjects who are more resistant to the 
pharmacological treatment. Indeed, miRNAs play an important regulatory role in all the biological pathways 
that are dynamically triggered by stress and they also represent one of the fastest and most dynamic response 
mechanism that can regulate gene transcription and protein translation in response to stress (Ebert and Sharp 
2012).  
This review focuses on the relationship between miRNAs, stress vulnerability or resilience and depression 
by discussing, both in rodents as well as in humans, how miRNAs can mediate the long lasting effect of 
stress on depression vulnerability or resilience and how changes in miRNAs expression can also mediate the 
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response to pharmacological treatments. To this purpose, we searched different combinations of keywords, 
such as “miRNA”, “stress”, “childhood trauma”, “depression”, “vulnerability”, “resilience”, “mouse”, “rats”, 
“animal models”, “biomarkers”, “antidepressant” and “antidepressant response”, using PubMed searching 
database references. In the following sections, the identified studies are reported in tables and the most 
important studies will be discussed.  
2. Effect of stress on miRNAs biogenesis  
Before discussing how stress can induce changes in the levels of miRNAs and of their target genes and 
signalling, we will introduce how stress can affect the entire process involved in the biogenesis of miRNAs.  
During the last years, several studies have investigated the exact role of miRNAs, from their production to 
their role as regulators of gene expression, in order to understand the key steps that can be affected by stress 
and thus involved in the pathogenesis of several psychiatric disorders, especially stress related disorders, like 
depression.   
MiRNAs are encoded as precursor-miRNAs (pre-miRNAs), long primary transcripts with a cap structure at 
the 5’ end and polyadenylation at the 3’ end. The processing of the pre-miRNAs starts by the cellular 
endonuclease Drosha with the microprocessor complex subunit DGCR8/Pasha. The pre-miRNA is cleaved 
by the endoribonuclease Dicer in cytoplasm, producing a short double stranded miRNA duplex, which is 
then processed in a mature miRNA. Subsequently, it is incorporated in the RNA-induced silencing complex, 
constituted by the components of the Argonaute family protein (Wahid et al. 2010; Nakanishi 2016). Mature 
miRNAs activate or repress the Wnt pathway at multiple levels by targeting Wnt ligand/receptor and ligand/
receptor associated proteins, β-catenin. Wnt activation increases the expression of miRNAs through the 
binding of β-catenin to transcription factors, which bind to promoter regions to activate transcription 
(Ghahhari and Babashah 2015; Peng et al. 2017). β-catenin protein plays a key protective role in stress 
conditions, upstream miRNA synthesis, through the control of the enzyme Dicer1 also according to a recent 
study conducted by Dias and co-workers (2014), and indeed, the presence of lower levels of Dicer1, as 
consequence of stress exposure, has been also associated with an enhanced vulnerability to stress (Lim et al. 
2011; Mori et al. 2012; Dias et al. 2014).  
For example, Wingo and collaborators (2015) investigated the impact of Dicer1 regulation in patients with 
post-traumatic stress disorder and with comorbid depression, reporting reduced levels of Dicer1 in patients 
as compared to controls, an effect that was replicated in other two independent cohorts (Wingo et al. 2015). 
Interestingly, several proteins involved in β-catenin activity control, including the enzyme Glycogen 
synthase kinase 3, have been found altered in depressed patients (Jope and Roh 2006; O’Brien and Klein 
2007).  
Similarly, He and colleagues (2012) reported an association between genes involved in miRNAs biogenesis 
with depression. Indeed, they investigated several single nuclear polymorphisms within several genes 
including DiGeorge syndrome chromosomal region 8 (DGCR8), Argonaute1 (AGO1) and Gem-Associated 
Protein4 in 314 depressed patients and 252 healthy controls and found that genetic variants within DGCR8 
(rs3757) and AGO1 (rs636832) increased the risk for depression (He et al. 2012). 
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3. Role of miRNAs in stress response and neuropathological conditions in 
humans  
The activation or the inhibition of transcription is often coordinated by the action of several miRNAs that act 
together in clusters (Catalanotto et al. 2016). Although several genes are responsive to a single miRNA and 
an individual gene can be targeted by several miRNAs, the ideal strategy would be to study the coordinated 
action of all the miRNAs and their target genes, the direction of the modulation of each miRNA and target 
gene, as well as to analyse the pathways and the complex networks in which they are involved (Carroll et al. 
2013).  
Studies on the changes in miRNAs levels in association with stress exposure or with depression in humans 
are only few in the literature and below here we reported and discussed the main studies conducted in post-
mortem brains, in peripheral blood and in sperm samples. In Table 1 we reported all the studies showing 
alterations in miRNAs levels in depressed patients or in subjects exposed to stress. We used as input 
keywords for Pubmed “miRNAs”, “Stress”, “Childhood Trauma”, “Depression”, “Resilience”, 
“Vulnerability”.  
3.1 Studies on post-mortem brains 
Most of the studies in the literature are focused on the possible role of miRNAs in driving the effect of stress 
exposure on depression vulnerability. For example, Smalheiser and collaborators (2012) investigated a 
miRNAs network in post-mortem brains of antidepressant-free depressed suicide patients by using multiplex 
RT-PCR, identifying a network of miRNAs able to target several genes, which have been already 
demonstrated to be involved in depression vulnerability. Indeed, they found that miRNAs expression was 
overall significantly down-regulated in cases versus controls, with a particular effect on 21 miRNAs, which 
have a common seed region (Smalheiser et al. 2012). Among the predicted targets of these 21 altered 
miRNAs, they found estrogen receptor alpha (ESR1), which resulted to be targeted by 3 different down-
regulated miRNAs (miR-148b, miR-301a, miR-496). Interestingly, ESR1 has been recently associated with 
resilience to depression (Lorsch et al., 2018). Moreover, among all the validated target genes of the 21 
modulated miRNAs they also found the DNA Methyltransferase 3 Beta (targeted by miR-148b), the Vascular 
endothelial growth factor A (VEGF-A) (targeted by miR-20b, miR-20a, miR-34a, miR-35b-5p), and the B-
cell lymphoma 2 (targeted by miR-34a) genes, that interestingly have been all already associated with 
depression vulnerability (Smalheiser et al. 2012). 
Maheu and colleagues (2015) analysed whether (and which) miRNAs can alter the neuronal response to 
Glial Cell Line-Derived Neurotrophic Factor (GDNF), which was previously related with coping stress 
abilities and associated with the neuroplasticity related mechanisms, and was also found reduced in 
depressed patients (Uchida et al. 2011; Lin et al. 2015). In particular the authors showed an inhibitory action 
of a specific miRNA, the miR-511, on the GDNF receptors expression (GFRα1a and GFRα1b) in depressed 
suicidal subjects’ post-mortem brains (Maheu et al. 2015). Their results showed that this inhibition occurs 
specifically and independently on the GFRα1a receptor, suggesting that the changes induced in GDNF 
signalling can be considered more in changing the quality, rather than the quantity, of GDNF signalling. 
!  3
In addition, miR-135a and miR-124-3p have been investigated as possibly involved in depression 
vulnerability (Issler et al. 2014; Roy et al. 2017). Issler and collaborators (2014) reported lower levels of 
miR-135a in the raphe nuclei of suicide victims as compared to control subjects and they also reported the 
same reduction at peripheral level (in plasma samples); in parallel, they also demonstrated alterations in 
miR-135a target genes involved in the regulation of Serotonin (5-HT) neuron-related genes such as the 5-HT 
transporter, SLC6A4, and the 5-HT receptor, HTR1A, suggesting a role for miR-135a as a potential blood 
biomarker for depression vulnerability (Issler et al. 2014). Another miRNA that has been implicated in 
depression vulnerability is the miR-124-3p, which Roy and colleagues (2017) found increased in the Pre-
Frontal Cortex of post-mortem brains of depressed patients as compared to controls. They also found 
reduced expression of miR-124-3p target genes Glutamate receptor 3, Glutamate receptor 4, and 
Glucocorticoid receptor (NR3C1), which are genes all involved in stress response and neuroplasticity (Roy 
et al. 2017). 
MiR-218, which targets Netrin-1 guidance cue receptor Deleted in Colorectal Cancer (DCC), has been 
proposed as a new epigenetic marker of stress vulnerability. Briefly, Torres-Berrio and collaborators (2017) 
investigated the mechanism of co-expression of DCC and miR-218 in pyramidal neurons of human pre-
frontal cortex. The expression of miR-218 and DCC was quantified in post-mortem prefrontal cortex tissue 
samples obtained from antidepressant-free depressed subjects who committed suicide and sudden-death 
controls, using Real Time PCR and immunofluorescence. They found increased DCC and reduced miR-218 
expression levels in the prefrontal cortex of depressed subjects in line with the expected inverse relationship 
between miRNAs and mRNA levels of target gene. Therefore, this imbalance between miR-218 and its target 
DCC levels could be a key mechanism of susceptibility to stress (Torres-Berrio 2017). 
3.2 Studies on Peripheral Blood, Cerebrospinal fluid and sperm samples 
As compared to the studies conducted in post-mortem brains, more lines of evidence on peripheral blood 
from subjects exposed to stressful events or from depressed patients are available in the literature.  
One of the first studies has been published by Fan and collaborators (2014) who identified changes in 26 
miRNAs in peripheral blood mononuclear cells obtained from 3 depressed patients compared to 3 control 
subjects using miRNAs microarray expression profiling. The authors validated the microarray results using 
Real Time PCR in an enlarged cohort of 91 depressed patients and 46 control subjects matched by age and 
gender. All the 26 miRNAs were upregulated in depressed patients except for miRNA-338 and, among these 
26 miRNAs, miRNA-26b, miRNA-1972, miRNA-4485, miRNA-4498, and miRNA-4743 demonstrated a 
significant difference. Investigating more in detail the pathways in which the significant altered miRNAs 
were involved, the authors observed a particular enrichment in pathways such as axon guidance, 
glutamatergic synapse, Wnt signalling pathway, ErbB signalling pathway, mTOR signalling pathway, VEGF 
signalling pathway and long-term potentiation, in line with literature data that suggest a possible 
involvement of these systems in the mechanisms related to depression development (Voleti and Duman 
2012; Fan et al. 2014; Abelaira et al. 2014).  
MiRNAs have been also investigated with the aim to identify a possible association with depressive 
symptomatology. For example, Wang and collaborators (2015) identified the miR-144-5p whose baseline 
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levels were reduced in depressed patients as compared to controls and were inversely correlated with 
MADRS-S scores, suggesting miR-144-5p as a possible biomarker associated with the severity of depression 
(Wang et al. 2015).  
Another miRNA that could be implicated in the physiopathology of depression is miR-16, via the modulation 
of serotonin transmitter system in the brain (Song et al. 2015). In particular miR-16 levels in the CSF from 
depressed patients were significantly lower than those in controls; moreover, CSF miR-16 was negatively 
correlated with Hamilton scores and positively associated with CSF serotonin levels, suggesting that the 
measurement of this miRNA in the CSF could be a promising biomarker for mood changes (Song et al. 
2015). 
Alterations in miR-132 and miR-182 have been associated with depression vulnerability via the modulation 
of Brain-Derived Neurotrophic Factor (BDNF) that plays an essential role in neurodevelopment and 
neuroplasticity and whose levels have been found reduced at peripheral and central level in depressed 
patients as compared to controls. Li and collaborators (2013) measured serum BDNF levels and a panel of 
miRNAs that target BDNF in 40 depressed patients versus 40 healthy controls, reporting lower BDNF levels 
in association with depression, whereas the levels of miR-132 and miR-182 were significantly increased (Li 
et al. 2013). A reduction in BDNF protein levels has been also suggested to promote the development of 
depression and its treatment resistance by several studies (Lee and Kim 2010; Ihara et al. 2016).  
A recent work of Gururajan and collaborators (2016) showed that let-7b and let-7c can regulate the 
expression of 27 genes in the PI3K-AKT-mTOR signalling pathway, which has previously been reported to 
be deregulated in depression. Indeed, the expression of the miRNA let-7b and let-7c was found significantly 
decreased in a group of treatment-resistant depressive patients compared with control subjects (Gururajan et 
al. 2016). 
The impact of miRNAs on depression vulnerability has been also evaluated from a genetic point of view; 
indeed, Liang and colleagues (2015) have investigated the possible contribution of single nucleotide 
polymorphisms in the promoters of let-7 family in the mechanisms of vulnerability for depression 
development, by genotyping 237 depressed patients and 296 healthy controls. The let-7 family has been the 
first to be discovered in humans with well-known key roles in neurogenesis and synapse formation (Rehfeld 
et al. 2015) and a possible involvement in depression development (Maffioletti et al. 2016). The authors 
showed that both the rs10877887CC and the rs13293512CC let-7 genotypes increased the risk for depression 
onset (Liang et al. 2015). 
Only a few studies have investigated the possible effects of stressful life events on miRNAs modulation in 
humans. Among them, Volk and colleagues (2016) suggested an important role for miR-15a in the 
development of coping strategies versus stressful exposures. Indeed, they analysed miR-15a expression 
levels in RNA samples from peripheral blood cells of young healthy male subjects following oral 
administration of the glucocorticoid receptor agonist dexamethasone, reporting a significant upregulation of 
miR-15a at 3- and 6-hours post-treatment, an effect that interestingly was also present in peripheral blood 
cells of control subjects exposed to childhood trauma as compared to non-exposed individuals. Given the 
previous evidence of the key role of the Hypothalamic-Pituitary-Adrenal (HPA) axis and of childhood 
trauma in the development of depression (Juruena 2014; Keller et al. 2017; Juruena et al. 2018), the authors’ 
findings indicate that miR-15a is potentially regulated by the activation of the stress hormone system in 
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humans and it is involved in stress vulnerability and in the possible correlated development of 
psychopathology (Volk et al. 2016). 
Recently, Dickson and collaborators (2018) have also investigated the effects of childhood trauma on 
miRNAs levels using a different biological matrix, the sperm of voluntary healthy subjects. As a first-level 
screen to find candidate miRNAs whose expression in sperm correlates with Adverse Childhood Experience 
(ACE) score, they selected sperm samples from five men with the highest ACE scores (≥4) and five with the 
lowest (0–1) and performed miRNAs array analysis on each sample. Multiple members of the miR-34/449 
family showed pronounced reduction in the group of subjects with highest ACE score, in particular 
miR-449a and miR-34c (Dickson et al. 2018). 
In conclusion, to date, literature data in human studies show several clues that give an idea of the possible 
contribution of epigenetic mechanisms in the vulnerability and/or resilience related to depression. Studies 
have focused more on significant changes in miRNAs levels and their targeting genes in depressed patients 
versus controls, taking only partially into account the possible effects of stressful life events and the related 
coping strategies. 
microRNA/Gene Methods Principal Findings Reference
DICER1 Genome-wide β-catenin enrichment 
mapping
β-catenin could have a 
protective role through 
miRNA production.
Dias et al. 2014
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DICER1 Genome-wide differential gene 
expression profiles in blood of PTSD 
and Depression cases versus controls 
with no PTSD and no depression.
DICER1 plays a role in 
molecular mechanisms of 
PTSD and Depression 
through the DICER1 and 
subsequent miRNA 
regulation pathway.
Wingo et al. 
2015
DGCR8, AGO1 
and GEMIN4
High-resolution melting and Real time 
PCR
Variants of DGCR8 rs3757 
and AGO1 rs636832 
increased depression risk.
He et al. 2012
Panel of 21 
miRNAs
Multiplex RT-PCR Overall miRNA expression 
was significantly down-
regulated in depressed 
suicide subjects versus 
control subjects.
Smalheiser et 
al. 2012
miR-511, GDNF Quantitative Real-Time PCR, miRNA 
transfections, immunoblotting and 
immunochemistry
An important role for 
GDNF in depression, in 
particular the fine 
regulation by miRNAs of 
isoform-specific GFRα1 
receptor in shaping 
neuronal responses to this 
neurotrophin.
Maheu et al. 
2015
miR-135a Western Blot and Real-time PCR miR135a levels in total 
blood of depressed human 
patients were reduced 
compared to those of 
healthy controls.
Issler et al. 
2014
miR-124-3p qPCR Significant increase in the 
expression of miR-124-3p 
in depressive group, 
comparing post-mortem 
brains of depressive 
subjects and control 
subjects.
Roy et al. 2017
miR-218, DCC Real-Time PCR and DCC 
immunofluorescence
miR-218 may be a switch 
of susceptibility versus 
resilience to stress-related 
disorders.
Torres-Berrio et 
al. 2017
miR-26b, 
miR-1972, 
miR-4485, 
miR-4498, 
miR-4743
qRT-PCR Expression levels of 5 
miRNAs were significantly 
upregulated in depressed 
patients compared to 
healthy controls.
Fan et al. 2014 
miR-144-5p Real-time PCR Plasma miR-144-5p levels 
in depressive patients were 
significantly lower than in 
healthy controls.
Wang et al. 
2015
miR-16 qRT-PCR CSF miR-16 decrease in 
drug-free depressive 
patients compared to 
control subjects.
Song et al. 2015
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Table 1. Summary of the studies showing alterations in miRNAs levels in depressed patients or in subjects 
exposed to stress.  
miR-132, 
miR-182
Real-Time PCR, ELISA Levels of miR-132 and 
miR-182 were crucial for 
BDNF regulation levels.
Li et al. 2013
miR-15a Real-time PCR and NGS sequencing 
(MiSeq)
Increased levels of miR-15a 
in blood of subjects 
exposed to childhood 
trauma or to the oral 
administration of 
Dexamethasone.
Volk et al. 2016
Let-7 family Polymerase chain reaction-restriction 
fragment length polymorphism and 
DNA sequencing assays
rs10877887 and 
rs13293512 polymorphisms 
in let-7 family are related to 
an increase risk to 
depression onset and 
worsening.
Liang et al. 
2015
Let-7b, let-7c qRT-PCR Let-7b and let-7c baseline 
expression decreased in 
treatment-resistant 
depressive patients 
compared with controls.
Gururajan et al. 
2016
miR-449a, 
miR-34c
Microarray analysis and qReal-Time 
PCR
miR-34/449 dysregulation 
in sperm of subjects 
exposed to trauma.
Dickson et al. 
2018
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4. Role of miRNAs in the mechanisms underlying stress vulnerability and 
stress resilience  
As we have already mentioned, stress is an important risk factor for the development of several psychiatric 
diseases, in particular depression (Tost 2015). The American Psychological Association (APA) has defined 
stress as “the physiological or psychological response to internal or external stressors” (APA 2018). 
However, the response and the impact of stress on each individual might be different, as it is not only 
attributable to the exposure to stressful events through lifetime, rather to a plethora of risk factors, including 
the individual genetic background, the environment and how these two factors interact with each other, a 
mechanism also known as Gene X Environment interaction.  
Based on this, although traumatic life events, especially those occurring early in life or during adolescence, 
represent an important clinical risk factor for the future vulnerability for depression, not all the exposed 
individuals develop stress-related psychiatric disorders, but some of them acquire coping strategies and 
become resilient (Wu et al. 2013; Pfau and Russo 2015). For this reason, the identification of molecular 
mechanisms and of biomarkers associated with vulnerability or resilience will help in the identification of 
subjects at high risk; monitoring and preventive programmes could be then proposed to the identified high-
risk individuals to minimize their susceptibility of developing psychopathology later in life.  
On the other hand, the identification of mechanisms underlying resilience might be useful for the 
identification of processes that confer “protection” versus stressful exposures, thus will be useful for the 
discovery of novel targets for the development of new drugs and preventive strategies. In this context, 
miRNAs might be a fundamental tool to recognize vulnerable or resilient subjects permitting to high-risk 
subjects to benefit from such preventive therapies.  
Unfortunately, up to now, most of the studies reported in literature analyses the effect of stress without 
focusing on potential differences in relation to stress vulnerability or resilience,. Accordingly, in this 
paragraph we will show the main findings regarding the effect of stress on miRNAs levels (Table 2), 
mentioning also the latest research on distinct miRNAs changes in relation to stress vulnerability and stress 
resilience (Table 3). To do this, we searched in Pubmed studies using the keywords: “stress” and “miRNAs” 
and we included only findings related to effect of stress on miRNAs modulation. Within the 11 relevant 
studies, all reported in Table 2, in the present paragraph we will deeply discuss only those that are focused on 
miR-124 and miR-16, as they are the most investigated miRNAs in the context of stress. 
One of the first study showing how stress affects miRNAs comes from Bahi and colleagues in 2014 which 
investigated the modulation of miR-124a in rats exposed to chronic social defeat stress, which consists of 
placing the animal in the home cage of an unfamiliar rat and in allowing them to interact until the intruder 
shows a defeat position for approximately 3 seconds. The authors reported higher levels of miR-124a in the 
hippocampus of stressed rats, whereas no differences were observed in their prefrontal cortex as compared to 
matched controls (Bahi et al. 2014). Interestingly, miR-124 directly targets and thus modulates the 
expression of the BDNF, which is known to modulate neurogenesis in the hippocampus and it is also 
involved in the pathophysiology of depression (Castren et al. 2007; D’Sa and Duman 2002; Duman and 
Monteggia 2006). In line with the presence of an up-regulation of miR-124a, Bahi and colleagues also found 
reduced BDNF levels in the hippocampus of the same animals supporting that BDNF gene expression can be 
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modulated by changes in miR-124a. The authors suggested that miR-124a might participate in the induction 
of depressive-like behaviour through the regulation of the BDNF gene expression (Bahi et al. 2014). In line 
with these results, the study of Cao and colleagues, showed that miR-124 is up-regulated in the hippocampus 
of rats exposed to a chronic unpredictable stress, suggesting again a role of miR-124 in depressive-like 
behaviour induced by stress (Cao et al. 2013). 
In addition, miR-16 has been suggested to participate in the mechanisms underlying stress response through 
the regulation of its target gene BDNF (Bai et al. 2012). The down-regulation of BDNF in the hippocampus 
of rodents has been associated with depressive like behaviour caused by different stress paradigms (Larsen et 
al. 2010). For instance, rats exposed to maternal deprivation and chronic mild stress, when compared to 
controls, exhibited a depressive-like behaviour which paralleled the presence of lower BDNF levels in the 
hippocampus and of an up-regulation of miR-16 expression levels (Bai et al. 2012).  
Now, we will discuss those studies showing changes in miRNAs expression levels related to stress 
vulnerability and resilience. Table 3 provides a summary of miRNAs associated with stress vulnerability and 
resilience of developing a psychiatric disease in animals. To this purpose, we searched in Pubmed for animal 
studies using the keywords “stress”, “miRNAs”, “vulnerability” and “resilience” and we found 8 relevant 
studies.  
In 2015, Chen and collaborators were one of the first researchers looking at vulnerability and resilience as 
different and distinct responses to stress. Animals were behaviourally tested and divided into the vulnerable 
or resilient group, depending on the delay latencies they used to display the defeat position: rats showing an 
average of latency score <300 s were classified as short latency rats and these animals represented the 
vulnerable group. On the other hand, the resilient group was represented by the long latency rats, which 
displayed a latency score >300 s.  MicroRNAs profiling on blood collected before the stress exposure 
showed four miRNAs significantly decreased in rats that developed a vulnerable phenotype: miR-24-2-5p, 
miR-27a-3p, miR-30e-5p and miR-362-3p. Conversely, after exposure to chronic stress, the expression levels 
of another panel of miRNAs (miR-139-5p, miR-28-3p, miR-326-3p and miR-99b-5p) were lower in animals 
showing a resilient phenotype (Chen et al. 2015). 
Whether a few studies analysed the entire profile of miRNAs by using ‘omics approaches, others focused the 
attention on single and specific miRNAs, such as miR-124 and miR-16 (Xu et al. 2017; Higuchi et al. 2016; 
Zukarew et al. 2016). For example, Xu and collaborators reported that rats exposed to a chronic 
unpredictable mild stress or treated with dexamethasone during adolescence showed an up-regulation of 
miR-124 expression levels in the basolateral amygdala as compared to non-stressed animals (Xu et al. 2017).  
The same miRNA was found reduced in the hippocampus of mice exposed to chronic ultra-mild stress, 
which consists of one-week period of repeated mild stressful events which developed depression-like 
behaviour, whereas the antidepressant imipramine (TCA) reverted the effect of stress (Higuchi et al. 2016). 
In the same study, the overexpression of the viral-mediated miR-124 in murine hippocampal neurons 
conferred behavioural resilience to chronic mild unpredictable stress, whereas the infusion of the anti-
miR-124 was able to drive  the development of enhanced vulnerability to a stress paradigm, supporting that 
the modulation of this miRNA can be helpful in discriminating between a stress resilient or a vulnerable 
phenotype. However, these results are in contrast with the increased expression levels of miR-124 in stressed 
!  10
animals reported in the previously described studies (Xu et al. 2017; Bahi et al. 2014; Cao et al. 2013). These 
discrepancies might be due to different animal species, to the stress paradigm and to their interactions. For 
this reason, further studies are required to identify how the interaction between genes and environment can 
modify the expression of small non-coding RNAs and their role in depression-like behaviour.   
MiR-16 represents another miRNA which has been investigated in relation to stress response.  It has been 
shown to be a key player in the hippocampal neurogenesis and a negative regulator of serotonin transporter 
(SERT) levels in raphe neurons after fluoxetine treatment (Baudry et al. 2010; Launay et al. 2011). Zurawek 
and colleagues showed an up-regulation of miR-16 expression levels in serum samples of resilient rats after 
one week of chronic mild stress paradigm as compared both to animals that developed an anhedonic-like 
phenotype and also to control animals (Zurawek et al. 2016). Furthermore, after 7 weeks of CMS, 
anhedonic-like animals showed a significantly down-regulated expression of miR-16 in the ventral tegmental 
area (VTA) and in the hippocampus as compared to control and resilient rats. The authors observed a steady 
increase of miR-16 levels from the 1st week to the 6th and 7th week of chronic mild stress paradigm, whereas 
no fluctuations were seen in the control or anhedonic-like animals during the entire stress paradigm period, 
suggesting an inadequate or insufficient copying response of vulnerable rats compared to controls (Zurakew 
et al. 2016).  
Besides miR-124 and miR-16, other miRNAs have been associated with resilience and/or vulnerability to 
stress, such as miR-9, miR-326 and miR-504. Zhang and colleagues investigated the role of miRNAs as 
possible mediators of the long-lasting effects of early life stress exposures on enhanced susceptibility to 
chronic stress in adulthood. Rats were exposed to maternal deprivation for the first 14 days of life and then 
daily exposed to a chronic unpredictable stress from week 10; a group of animals was also treated with 
escitalopram from week 14 with a daily 4-weeks intraperitoneally infusion. MiR-9 was found to be down-
regulated in the striatum of both rats exposed to maternal deprivation with or without exposure to chronic 
mild stress, whereas miR-326 were down-regulated only in rats exposed to chronic mild stress, suggesting 
that only miR-326 is sensitive to stress in adulthood. Furthermore, escitalopram did not normalize the 
decreased levels of miR-9, whereas alterations in miR-326 levels were reverted by 4-weeks of treatment. The 
authors suggested that maternal deprivation enhanced the development of depression-like behaviours and 
increased resistance to escitalopram treatment in rats by promoting a down-regulation of miR-9, whereas 
miR-326 could represent a new target for antidepressant drugs (Zhang et al. 2015). This study is in line with 
the previous findings showing the presence of an up-regulation of miR-504 which paralleled a down-
regulation of dopamine receptor 2 (DRD2) in rats’ nucleus accumbens, in association with enhanced 
vulnerability to stress in adulthood in rats exposed previously to maternal deprivation (Zhang et al. 2013).  
Lastly, Pearson-Leary and colleagues identified miR-455-3p and miR-30e-3p as involved in the development 
of stress copying strategies in rats exposed to chronic social defeat stress. The rats were exposed to social 
defeat for 7 days and then behaviourally tested to identify vulnerable or resilient animals; interestingly, 
increased miR-455-3p levels were specifically observed in the ventral hippocampus (vHPC) of resilient 
mice, whereas an increase in miR-30e-3p levels was observed in vulnerable mice. Pathway analyses 
identified inflammatory and vascular remodelling pathways as enriched by genes targeted by these 
!  11
microRNAs, suggesting that inflammatory processes and vascular remodelling in the vHPC, might be 
directly related to the development of vulnerability to stress (Pearson-Leary et al. 2017).  
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Table 2. List of studies reporting miRNAs modulated by stress exposure.  
miRNAs modulated by stress exposure
miRNA Stressful Paradigm References
miR-134 Chronic unpredictable mild stress Yu et al. 2018
miR-9-5p  
miR-128-1-5p  
miR-382-5p  
miR-16-5p  
miR-129-5p  
miR-219a-5p
Chronic mild stress Buran et al. 2017
miR-135a 
miR-16 Inescapable stress Liu et al. 2017
miR-124 Chronic social defeat Chronic unpredictable mild stress
Bahi et al. 2014 
Cao et al. 2013
miR-17-92 Jin et al. 2016
Several known miRNAs Chronic unpredictable mild stress Ma et al. 2016
miR-383  
miR-764 Chronic unpredictable mild stress Duan et al. 2016
16 miRNAs Electro-acupuncture Duan et al. 2016
miR-10B Chronic unpredictable stress  Sleep deprivation Jiang et al. 2015
miR-16 Maternal deprivation and unpredictable stress Bai et al. 2012
miR-34c
Acute restraint stress and chronic 
social defeat stress Haramati et al. 2011
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Table 3. List of studies reporting involvement of miRNAs in the mechanisms associated with resilience and/
or vulnerability to stress. 
miRNAs involved in stress resilience and vulnerability
miRNA Stressful Paradigm References
miR-455-3p  
miR-30e-3p
Chronic social defeat Pearson-Leary et al. 2017
miR-124 Chronic unpredictable mild stress Chronic ultra-mild stress
Xu et al. 2017 
Higuchi et al. 2016
miR-16 Chronic mild stress Zukarew et al. 2016
miR-24-2-5p 
miR-27a-3p 
miR-30e-5p 
miR-362-3p 
miR-139-5p 
miR-28-3p 
miR-326-3p 
miR-99b-5p
Chronic social defeat Chen et al. 2015
miR-9 
miR-326
Maternal deprivation 
Chronic unpredictable stress Zhang et al. 2015
miR-504 Maternal deprivation Zhang et al. 2013
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5. Antidepressant drugs and miRNAs  
Antidepressant research is currently booming as consequence of the avowal of the burden of depression that 
is one of the most common medical condition worldwide and the leading cause of disability (World Health 
Organisation, WHO, 2018). The Guidelines for the treatment of depression indicate as first-line treatments 
the selective serotonin reuptake inhibitors (SSRIs), serotonin noradrenaline reuptake inhibitors (SNRIs), and 
other antidepressant drugs including agomelatine, bupropion, mirtazapine and vortioxetine (Mora et al. 2018; 
Kennedy et al. 2016). Furthermore, approximately a third of depressed patients treated with first line 
antidepressants report low or absent symptomatology improvement, ending up with dropping out the therapy, 
or leading to unhealthiest consequences, such as the worsening of symptomatology and even suicide. With 
the aim of improving treatment response and reducing the burden of depression worldwide, researches are 
focused on the identification of peripheral biomarkers able to predict the treatment response or the onset of 
side effects.   
In this context, giving the possible role of miRNAs in the pathogenesis of depression, a growing body of 
evidence has suggested that changes in miRNAs expression may participate not only in the development of 
the disease, but also in the efficacy of antidepressant treatment. Thus, miRNAs could represent useful 
biomarkers associated with the disease status and that can predict the treatment response. In the following 
paragraphs, we will review studies showing an association between changes in miRNAs expression and 
antidepressant drug response. A summary of all the studies on miRNAs and treatment response in humans 
are provided in Tables 4, whereas those performed in animal models are shown in Table 5.  
5.1 Human studies 
Despite the efforts in the identification of predictors for the antidepressant response and the growing 
evidence of a possible application of miRNAs, poorly has been discovered in humans. Several miRNAs have 
been found associated with depression, but only a few studies have identified miRNAs as possible predictors 
of the antidepressant response. In Table 4 we presented all the clinical studies focused on the antidepressant 
drug response and miRNAs modulation in depressed patients. To identify the mentioned studies, we searched 
in Pubmed by using the keywords: “miRNAs”, “antidepressants”, “antidepressant response” and 
“biomarker”. We found 19 relevant studies and in the current paragraph we will focus on the most 
investigated miRNAs:miR-1202, miR-16 and miR-124. 
MiRNA-1202, a brain specific miRNA, regulates the glutamate metabotropic receptor 4 (GRM4) that is 
involved in the glutamatergic, dopaminergic, GABAergic and serotoninergic transmission (Pilc et al. 2008), 
due to its pre-synaptical location at both glutamatergic and non-glutamatergic synapses (Bradley et al. 1996). 
Therefore, GRM4, in addition to regulate the glutamatergic transmission, might act as pre-synaptic regulator 
for the release of other neurotransmitters (Cartmell 2000). Due to its involvement in several biological 
processes which have been associated with both the depression development as well as the drug response 
(Lopez et al. 2014), the miR-1202 has been proposed as a novel potential target for the development of new 
antidepressant compounds (Davis et al. 2012, 2013).  In this context, Lopez and colleagues showed reduced 
miR-1202 levels in post-mortem brains, specifically in the prefrontal cortex, of depressed patients without a 
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history of antidepressant treatment compared to depressed subjects treated with antidepressant drugs. The 
role of miR-1202 in the mechanisms of action of antidepressant drugs has been also investigated in neural 
precursor cells (NPCs), which have been treated with citalopram (SSRI) and imipramine (TCA) both acutely 
(24 hours) and chronically (15 days). Only the chronic treatment showed an up-regulation of miR-1202 
expression levels, followed by a reduction of GRM4 mRNA (Lopez et al. 2014). 
Furthermore, Lopez and colleagues investigated the regulation of miR-1202 in relation with citalopram 
treatment. Interestingly, patients who responded to the treatment showed, at baseline, lower miR-1202 
plasma levels as compared to both controls and non-responders, whereas after 8 weeks of treatment the 
miR-1202 expression levels in responders reached a peak, exceeding the levels observed in controls (Lopez 
et al. 2014), suggesting a possible role of miR-1202 as a biomarker for antidepressant response. Moreover, a 
similar trend for decreased levels of miR-1202 at baseline was observed also in two other independent 
cohorts of depressed patients who responded to 8-weeks with escitalopram (SSRI) and desvelfaxine, (SNRI) 
treatment (Fiori et al. 2017). Indeed, in line with the results of Lopez and colleagues, 8 weeks of 
antidepressant treatment increased miR-1202 expression levels compared to baseline also in these cohorts 
(Fiori et al. 2017). Moreover, this study suggests that miR-1202 levels predict the non-responsiveness to 
antidepressant treatment with a sensitivity of 91,7% and a specificity of 57,7% (Fiori et al., 2017).  
MiR-16 has been widely involved in the pathophysiology of depression; for examples, Baudry and 
colleagues demonstrated that the serotonin transporter (SERT) expression, a well-known vulnerability gene 
for depression, is modulated by miR-16 in 1C11 neuroectodermal cell line (Baudry et al. 2010). In particular, 
in these cells the over-expression of miR-16 resulted in a decrease of SERT protein levels as the inhibition of 
the miRNA unlocks the SERT protein expression. Accordingly, the work of Song and collaborators showed a 
down-regulation of miR-16 expression levels in CSF of drug-free depressed patients compared to controls as 
well as reduced CSF serotonin levels, since the down-regulation of miR-16 produces an up-regulation of 
SERT and the subsequent increase of serotonin re-uptake (Song et al. 2015). Given these findings, researches 
tried to visualise a possible application of miR-16 as a biomarker for antidepressant drug effect.  For 
example, Li and colleagues showed increased miR-16 levels in depressed patients after 4 weeks of SSRI 
treatment compared to baseline. However, no changes in miR-16 levels were found in the group of patients 
treated with SNRI, suggesting that different antidepressant drugs might differently affect specific sets of 
miRNAs (Lin et al. 2018).  
Interestingly, the serotonin transporter and the serotonin receptor-1a transcripts are also targeted by miR-135. 
Issler and colleagues showed increased blood miR-135 levels in depressed subjects undergoing cognitive 
behavioural therapy (CBT), but not in depressed patients treated with escitalopram for 12-weeks, suggesting 
that miR-135a in human blood might be a possible biomarkers for the antidepressant drug effect but larger 
cohorts are required to investigate its possible clinical involvement (Issler et al. 2014). 
MiR-124 regulates growth, proliferation and apoptosis in the central nervous system (Cheng et al. 2009) and 
a significantly higher expression of miR-124 in PBMCs has been reported in depressed patients, at baseline 
before escitalopram treatment, and the levels sharply decreased after 8 weeks of therapy, especially in 
responders, suggesting a role of this miRNA as modulator of treatment effect (He et al. 2016). These results 
have been also validated in other cohorts where He and colleagues showed that miR-124 levels were reduced 
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after 4 weeks of treatment with the traditional Chinese antidepressant medicine Chaihu-Shigau-San and that 
this miRNA decrease paralleled an upregulation of the mRNA and protein levels of the miR-124 predicted 
target genes mitogen-activated protein kinase 14 (MAPK14) and glutamate receptor subunit 3 (Gria3) (Liu et 
al. 2018).  
5.2 Animal Models  
In order to identify and discuss papers describing miRNAs modulated by antidepressant drugs and that might 
be potential biomarkers for antidepressant response, we searched in Pubmed using the following keywords: 
“animal models”, “rats”, “mouse” “miRNAs”, “antidepressants”, “antidepressant response” and 
“biomarkers” and we considered only studies describing the role of miRNAs in the mechanisms underlying 
the effects of antidepressant drugs.  We found 15 relevant studies (Table 5) and in the present paragraph we 
have decided to describe the effect of pharmacological treatment on miR-16 and miR-124, as they have been 
investigated in at least two studies.  
Among the plethora of miRNAs related to antidepressant treatment, miR-16 has been suggested to be a 
promising miRNA able to mediate the effect on hippocampal neurogenesis induced by SSRI treatment 
(Launay et al. 2011). Interestingly, Launay and colleagues showed that a three-days stereotaxic injection in 
the raphe with the SSRI fluoxetine down-regulated miR-16 in mice hippocampus, an effect which also 
correlated with an increase in SERT expression. Conversely, the direct injection of anti-miR-16 in the 
hippocampus increased the levels of SERT, similarly to fluoxetine injection in the raphe. These findings 
suggest that the fluoxetine-mediated down-regulation of miR-16 in the hippocampus has an antidepressant 
activity (Launay et al. 2011). However, the data are in contrast with the results of the study on human 
cohorts, previously described (Song et al. 2015; Li et al. 2018).  A rigorous attention to miR-16 activity has 
been paid also by Baudry and colleagues (2010) as they showed an increase in miR-16 expression levels in 
the raphe of mice which were infused with fluoxetine for 3 days. The fluoxetine-induced upregulation of this 
miRNA is probably due to the activity of a pre/pri-miRNA-16, whose levels are inversely correlated to those 
of the mature miRNA (Baudry et al. 2010). On the other hand, a twenty-days infusion of fluoxetine reduced 
miR-16 expression both in mice hippocampus and raphe (Baudry et al. 2010; Launay et al. 2011).  
In the study of Pan and Liu, miR-124a was shown to be modulated by the administration of the 
antidepressant drug duloxetine. Adult mice were exposed to a set of chronic unpredictable mild stressors for 
4 weeks and then received the SNRI drug for 3 weeks. The authors observed an up-regulation of miR-124a 
and miR-134 in the hippocampus of mice exposed to the stress paradigm, whereas miR-132 and miR-18 
were down-regulated.  After the administration of duloxetine, the elevated levels of both miR-124a and 
miR-134 significantly dropped, suggesting that the modulation of these levels was directly mediated by the 
SNRI drug (Pan and Liu 2015). The modulation of miR-124a by antidepressant drugs was investigated also 
by Higuchi and colleagues in a group of mice exposed to chronic ultra-mild stress. The animals were 
exposed to the stressful paradigm for 6 weeks and were administered the tricyclic antidepressant drug 
imipramine for the last 3 weeks of the paradigm. The levels of pre/pri mir-124a and the mature miR-124a 
were downregulated in the hippocampus of stressed mice and this effect was blocked by the administration 
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of imipramine, both for pre/pri and the mature miR-124a, suggesting that the modulation of miR-124a is 
mediated by imipramine (Higuchi et al. 2016). 
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miRNAs Samples/Tissue Antidepressant 
Drug
Results References
miR-134 ginsenoside Rg1 g i n s e n o s i d e R g 1 m a y 
exhibit neuroprotection and 
antidepressant-like effects 
by activating the CREB-
BDNF system within the 
BLA in this rat model of 
depression.
Yu et al. 2018
m i R - 1 6 , 
m i R - 3 0 , 
m i R - 3 4 , 
m i R - 1 2 8 , 
m i R - 1 3 2 , 
m i R - 1 3 4 , 
m i R - 1 8 2 , 
m i R - 1 8 3 , 
m i R - 1 8 5 , 
miR-212
Serum Different SSRI and 
SNRI
In patients treated with 
S S R I , m i R - 1 6 l e v e l s 
increased significantly after 
t r e a t m e n t . T h e r e f o r e , 
miR-183 and miR-212 
l e v e l s i n c r e a s e d 
significantly after four 
weeks of antidepressant 
treatment.
Lin et al. 2018
miR-451a  
miR-34a-5p  
miR-221-3P
Serum Paroxetine Depressed patients had 
lower serum miRNA-451a 
b u t h i g h e r s e r u m 
m i R N A - 3 4 a - 5 p a n d 
miRNA-221-3p, and these 
miRNAs are potent ia l 
predictors of the efficacy of 
antidepressants.
Kuang et al. 2018
miR-151a-3
p 
miR-221/22
2
Lymphoblastoid 
cell lines 
SSRI (paroxetine) miR-151a-3p, miR-221/222 
and their (here confirmed) 
respective target-genes, 
CHL1 and ITGB3, are 
i m p l i c a t e d i n S S R I 
r e s p o n s i v e n e s s , a n d 
possibly in the clinical 
response to antidepressant 
drugs.
Oved et al. 2017
miR-130b  
m i R - 2 6 a /
26b 
let-7f 
miR-770-5p  
miR-34c-5p
H u m a n U 8 7 
g l i o b l a s t o m a 
cells
Escitalopram Significant increase of 
let-7f, both after 48h and 
72h (p=0.022) of treatment 
and of  
miR-26a after 48h. 
Maffioletti et al. 
2017
miR-146a-5
p 
miR-146b-5
p 
miR-425-3p  
miR-24-3p
Blood Duloxetine O u r r e s u l t s r e v e a l e d 
differential expression of 
miR-146a-5p,  
miR-146b-5p, miR-425-3p 
and miR-24-3p according to 
treatment response. These 
miRNAs are consistent 
m a r k e r s o f t r e a t m e n t 
response and regulators of 
MAPK/Wnt systems.
Lopez et al. 2017
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miR-1202  
miR-135a  
miR-16
Blood Escitalopram or  
Desvenlafaxine or  
Duloxetine 
In two different cohorts, 
responders displayed lower 
baseline miR-1202 levels 
c o m p a r e d w i t h n o n -
responders, which increased 
following treatment.
Fiori et al. 2017
miR-1202 Blood Desvenlafaxine Changes in per ipheral 
miR-1202 levels were 
therefore associated with 
changes in brain activity and 
connectivity in a network of 
brain regions associated 
w i t h d e p r e s s i o n a n d 
antidepressant response. 
Lopez et al. 2017
miR-572  
miR-663a
Neuroblastoma 
cell lines
Fluoxetine  Fluoxetine could increase 
the expression of miRNAs 
in undifferentiated neural 
cells, and that putative target 
genes of those miRNAs 
have been shown to be 
involved in fundamental 
n e u r o d e v e l o p m e n t a l 
processes.
Mundalil Vasu et al. 
2016
414 miRNAs Blood Citalopram 414 miRNAs may regulate 
one or several modules 
associated with  
clinical improvement. By 
contrast, only 12 miRNAs 
w e r e p r e d i c t e d t o 
s p e c i f i c a l l y r e g u l a t e 
m o d u l e s u n r e l a t e d t o 
clinical improvement. 
Belzeaux et al. 2016
S e v e r a l 
miRNAs
Blood Escitalopram 40 different miRNAs were 
differently expressed after 
treatment; twenty-three 
significantly overexpressed 
and 17 down-regulated.
Enatescu et al. 2016
miR-124 PBMC D i f f e r e n t 
antidepressant drugs
The expression levels of 
miR-124 from PBMCs in 
M D D p a t i e n t s w e r e 
significantly higher than 
those in healthy controls. In 
addition, the expression 
levels of miR-124 were 
s i g n i f i c a n t l y d o w n -
regulated after eight weeks 
of treatment.
He et al. 2016
miR-355 Blood Citalopram A n t i d e p r e s s a n t d r u g 
treatment with citalopram 
can upregulate miR-335 
e x p r e s s i o n a n d 
d o w n r e g u l a t e G R M 4 
expression.
Li et al. 2015
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Table 4. Summary of miRNAs modulated by antidepressant drugs in human samples.   
miR-135 Blood Escitalopram Trend for higher expression 
after CBT vs escitalopram
Issler et al. 2014
miR-1202 Human Neural 
Progenitor cells 
(NPCs) and 
Whole Blood
Citalopram or  
Imipramine
miR-1202 is associated with 
the pathophysiology of 
depression and is a potential 
t a r g e t f o r n e w 
antidepressant treatments.
Lopez et al. 2014
miR-221  
miR-222
H u m a n 
Lymphoblastoid 
ccell lines
Paroxetine Decreased expression of 
miR-221 and miR-222 after 
paroxetina treatment, both 
predicted to target ITGB3. 
Oved et al. 2013
30 miRNAs Blood Escitalopram T h i r t y m i R N A s w e r e 
differentially expressed after 
the AD t rea tment : 28 
miRNAs were up-regulated, 
a n d 2 m i R N A s w e r e 
strongly down-regulated
Bocchio-Chiavetto 
et al. 2013 
miR-151-3p  
miR-212  
miR-132  
miR-30b*  
let-7b  
let-7c
H u m a n 
Lymphoblastoid 
ccell lines
Paroxetine These miRNAs has a 
potential values as SSRI 
response 
biomarkers.
Oved et al. 2012
miR-145  
miR-20b
PBMC P e r s o n a l i z e d 
antidepressant
Both miRNAs increase in 
expression level during 
treatment in responders.
Belzeaux et al. 2012
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miRNAs Samples/Tissue Antidepressant 
Drug
Results References
64 miRNAs H i p p o c a m p u s 
(mice)
Paroxetine 6 4 m i R N A s s h o w e d 
significant changes between 
fluoxetine treatment and 
control groups by analyzing 
626 mouse miRNAs.
Miao et al. 2018
miR-448-3p  
miR-764-5p  
miR-1264-3p  
miR-1298-5p  
miR-1912-3p
H i p p o c a m p u s 
(mice)
Ketamine A d m i n i s t r a t i o n o f a n 
a n t a g o n i s t t o m i R N A 
448-3p diminished the 
antidepressant effect of 
ketamine in the learned 
helplessness paradigm, 
indicating that up-regulation 
of miRNA 448-3p provides 
an antidepressant action.
Grieco et al. 2017
miR-124 Hippocampus  
(mice)
Imipramine Mouse exposed to chronic 
unpredictable mild stress 
expressed reduced miR-124 
levels in hippocampus. This 
e f f e c t i s r e v e r t e d b y 
imipramine. 
Higuchi et al. 2016
miR-132  
miR-18a  
miR-134  
miR-124a
Frontal lobe and 
h i p p o c a m p u s 
(mice)
Duloxetine A significant upregulation 
of miR-132 and miR-18a in 
hippocampus  
in the duloxetine treatment 
group compared with model 
group, whereas the levels of 
miR-134 and miR-124a 
w e r e s i g n i f i c a n t l y 
downregulated. miR-18a 
s h o w e d s i g n i f i c a n t 
upregulation in frontal lobe 
in the duloxetine treatment 
group relative to model 
group.
Pan and Liu 2015
miR-9  
miR-326
Brain tissue (rat) Escitalopram Early life stress enhanced 
the susceptibility to late life 
stress and  
resistance to escitalopram 
t r e a t m e n t t h r o u g h 
decreasing microRNA-9 
expression and subsequently 
upregulat ing dopamine 
receptor D2 expression in 
the nucleus accumbens. 
microRNA-326 may be a 
novel target of escitalopram.
Zhang et al. 2015
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miR-135 Imipramine or  
Fluoxetine
Chronic treatment with 
imipramine or fluoxetine 
(but not with reboxetine) is 
able to up-regulate miR-135 
in a chronic social defeat 
mice, a well-established 
model of depression.
Issler et al. 2014
miR-132 H i p p o c a m p u s 
(male mice)
Oleanolic acid The oleanolic acid induces 
the upregulation of  
miR-132, activating of the 
hippocampal BDNF-ERK-
CREB signalling pathways
Yi et al. 2014
15 common 
miRNAs
H i p p o c a m p u s 
(mice)
7-Chlorokynurenic 
acid (7-CTKA)
The 15 miRNA targets 
shared by TrkB-ERK/Akt 
pathways might participate 
in rapid-acting molecular 
m e c h a n i s m o f 
antidepressant 7-CTKA
Liu et al. 2014
miR-206 H i p p o c a m p u s 
(rat)
Ketamine miR-206 is involved in 
novel therapeutic targets for 
the anti-depressive effect of 
ketamine
Yang et al. 2014
miR-125  
miR-182
H i p p o c a m p u s 
(rat)
Chaihu Shugan 
San
miR-125a and miR-182 
recover to normal after 
intervention with Chaihu 
Shugan San, which may be 
the target points of its 
antidepressant effect.
Cao et al. 2013
miR-1971 P r e f r o n t a l 
cortices (PFCs)
Fluoxetine The therapeutic action of 
fluoxetine in shocked mice 
is  
associated with a significant 
reduction in mmu-miR-1971 
expression
Schmidt et al. 2013
miR-212 Denta te g i rus 
(rat) and  
Blood
Electroconvulsive 
stimulation (ECS)
miRNA miR-212 were 
significantly increased in rat 
dentate  
gyrus following both acute 
and chronic ECS. MiR-212 
levels also increased in 
whole blood following 
chronic ECS.
Ryan et al. 2013
miR-598-5p H i p p o c a m p u s 
(rat)
Electroconvulsive 
Shock Therapy 
and  
Ketamine
Electroconvulsive shock 
therapy and Ketamine 
possessed miR-598-5p as a 
common target.
O'Connor et al. 
2013
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Table 5. Summary of miRNAs modulated by antidepressant drugs in animal models.   
miR-16 H i p p o c a m p u s 
(mouse)
Fluoxetine F luoxe t ine , ac t ing on 
serotonergic raphe neurons, 
decreases the  
amount of miR-16 in the 
hippocampus, which in turn 
increases the levels of the 
s e r o t o n i n t r a n s p o r t e r 
(SERT).
Launay et al. 2011
miR-16 Raphe Nucle i 
(mouse)
Fluoxetine In mice, chronic treatment 
with the SSRI fluoxetine 
(Prozac) increases miR-16 
levels in serotonergic raphe 
nuclei, which reduces SERT 
expression
Baudry et al. 2010
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6. miRNA-based therapeutics 
RNA interference (RNAi) is a regulatory mechanism based on the use of small double-stranded RNA 
(dsRNA) molecules as triggers to direct homology-dependent control of gene activity (Almeida et al. 2005). 
The RNAi can be artificially induced by introducing a small double-stranded fragment of RNA, which 
corresponds to a particular mRNA into a cell.  The RISC complex within the cell recognizes this double-
stranded RNA fragment and uses the guide strand to bind and destroy its corresponding cellular mRNA 
target, blocking the translation of the encoded protein. Indeed, as the dysregulation of miRNA expression 
and the subsequent absence of mRNA regulation could lead to a general deregulation of tissue-specific gene 
expression, contributing to the development of diseases, the modulation of miRNA expression might be an 
innovative therapeutic tool, as the artificial RNAi could potentially block the translation of specific proteins, 
which play a pathological role in the development of psychiatric diseases (Castanotto and Rossi 2009).  
Similarly, transfection of miRNAs mimics represents another technique that is increasingly being used to 
over-express a specific miRNA and, therefore, to examine its biological effects on cell function. Generally, 
the mimic, which contains the same sequences of the endogenous miRNA of interest, can increase its 
expression levels (Matsukura et al., 2016), allowing to reveal the effects of the miRNA over-expression on 
biological functions.    
However, to date, several drawbacks and challenges of both miRNAs silencing and gain-of-function 
experiments in the research of psychiatric disorders are still unsolved. 
The first RNA-based therapeutic strategies had very low bioavailability due to the potential degradation of 
the oligonucleotides by RNase in serum or in endocytic compartment of cells (Rupaimoole and Slack. 2017). 
Moreover, the difficulties of reaching the target site by RNA-drugs are noteworthy due to the difficulties to 
targeting the oligodendrocytes to specific tissue and body fluids. Due to all these issues, the initial studies 
were mostly unsuccessful and the need to improve the methodology resulted urgent and necessary. In order 
to bypass obstacles related to the bioavailability, the oligonucleotides underwent different strategies: i) 
modifying the chemistry of oligodendrocytes by altering the nucleotides backbone or adding 
phosphonothioate groups; ii) developing delivery systems able to circumscribe miRNAs. The former 
approach has been the most widespread, whereas, recently, more efforts have been made in order to develop 
non-toxic and safe delivery systems.  
To date, no miRNA-based therapeutics have been approved by FDA (Food and Drug Administration) or 
EMA (European Medicines Agency) and the majority are still in the preclinical phase or are entering clinical 
trials. The therapeutic miRNAs that are in the developmental phase are engineered to treat mainly cancers 
and hepatitis C virus related disorders, as well as cardiovascular diseases (Chakraborty et al. 2017). 
Unfortunately, no miRNA-based therapeutics for the treatment of psychiatric disease have reached the pre-
clinical stage during the past years, showing the urgent need to increase the efforts of identifying clear 
miRNAs targeting molecules known to be involved in the pathogenesis or development of psychiatric 
disease.  
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7. Conclusions  
According to the World Health Association, depression in the first invalidated disease worldwide and the 
burden of depression is increasing year by year. Beside the well-known biological causes of depression, such 
as the depletion of monoamines and the neurotrophic hypothesis, stress is another cause deeply involved in 
the onset of depression, due to the deregulation of the HPA axis. Nowadays, stress is inevitably part of our 
everyday life and, during the lifespan, we are likely experiencing stressful events from childhood to later in 
life. However, whether several people worldwide might come across traumas during childhood or 
adolescence or adulthood, fortunately not all develop psychiatric diseases such as depression. For this 
reason, during the last decades researchers have focused their attention on the identification of stress copying 
mechanisms able to explain the resilience or vulnerability of developing psychiatric diseases. In this context, 
researchers have paid close attention on several genetic and epigenetic mechanisms involved in the 
dysregulation of the brain homeostasis; among the plethora of biological mechanisms which could be 
involved, epigenetic modifications, especially miRNAs, have drawn the attention of the scientists. MiRNAs 
are involved in the onset of depression as well as in the vulnerability and/or resilience to stressful events and 
the subsequent onset of depression. Both animal and human studies have shown that some miRNAs might be 
considered as biomarkers due to their different expression after stress exposure and predicting the onset of 
psychiatric conditions. For this reason, the evaluation of miRNAs expression in peripheral blood or  tissues 
might be a breakthrough in the diagnosis and prevention of depression.  
Moreover, the burden of depression is exacerbated by the lack of efficacy of antidepressant drugs, given that 
about 30% of depressed patients do not respond to the first-line antidepressant therapy. As a consequence, 
both new antidepressant drugs and pharmacological targets are extremely needed to improve the 
antidepressant therapy. A few studies have implied miRNAs as therapeutic tools to regulate the expression of 
genes involved in the pathogenesis of diseases; however, no miRNAs for depression or psychiatric diseases 
have been approved by Authorities (FDA or EMA) or even enter into clinical trials. Therefore, further studies 
are strongly required to find new antidepressant targets and to employ miRNAs in the clinical settings.  
In conclusion, given that miRNAs are involved in the pathogenesis of depression and in stress resilience and 
vulnerability, they might be implied also in predicting the antidepressant response or might be used as proper 
antidepressant drugs.  
!  26
8. Bibliography 
Abelaira HM, Reus GZ, Neotti MV, Quevedo J. The role of mTOR in depression and antidepressant 
responses. Life Sci 2014; 101(1-2): 10-14. 
Almeida R, Allshire RC. RNA silencing and genome regulation. Trends Cell Biol 2005; 15(5): 251-258. 
Bahi A, Chandrasekar V, Dreyer JL. Selective lentiviral-mediated suppression of microRNA124a in the 
hippocampus evokes antidepressants-like effects in rats. Psychoneuroendocrinology 2014; 46: 78-87. 
Bai M, Zhu X, Zhang Y, Zhang S, Zhang L, Xue L et al. Abnormal hippocampal BDNF and miR-16 
expression is associated with depression-like behaviors induced by stress during early life. PLoS One 
2012; 7(10): e46921. 
Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281-297. 
Baudry A, Mouillet-Richard S, Schneider B, Launay JM, Kellermann O. miR-16 targets the serotonin 
transporter: a new facet for adaptive responses to antidepressants. Science 2010; 329(5998): 
1537-1541. 
Belzeaux R, Bergon A, Jeanjean V, Loriod B, Formisano-Treziny C, Verrier L et al. Responder and 
nonresponder patients exhibit different peripheral transcriptional signatures during major depressive 
episode. Transl Psychiatry 2012; 2: e185. 
Belzeaux R, Lin CW, Ding Y, Bergon A, Ibrahim EC, Turecki G et al. Predisposition to treatment response in 
major depressive episode: A peripheral blood gene coexpression network analysis. J Psychiatr Res 
2016; 81: 119-126. 
Bocchio-Chiavetto L, Maffioletti E, Bettinsoli P, Giovannini C, Bignotti S, Tardito D et al. Blood microRNA 
changes in depressed patients during antidepressant treatment. Eur Neuropsychopharmacol 2013; 
23(7): 602-611. 
Bradley SR, Levey AI, Hersch SM, Conn PJ. Immunocytochemical localization of group III metabotropic 
glutamate receptors in the hippocampus with subtype-specific antibodies. J Neurosci 1996; 16(6): 
2044-2056. 
Brummer A, Hausser J. MicroRNA binding sites in the coding region of mRNAs: extending the repertoire of 
post-transcriptional gene regulation. Bioessays 2014; 36(6): 617-626. 
Buran I, Etem EO, Tektemur A, Elyas H. Treatment with TREK1 and TRPC3/6 ion channel inhibitors 
upregulates microRNA expression in a mouse model of chronic mild stress. Neurosci Lett 2017; 656: 
51-57. 
Bushati N, Cohen SM. microRNA functions. Annu Rev Cell Dev Biol 2007; 23: 175-205. 
Cao MQ, Chen DH, Zhang CH, Wu ZZ. [Screening of specific microRNA in hippocampus of depression 
model rats and intervention effect of Chaihu Shugan San]. Zhongguo Zhong Yao Za Zhi 2013; 38(10): 
1585-1589. 
Carroll AP, Tooney PA, Cairns MJ. Design and interpretation of microRNA-reporter gene activity. Anal 
Biochem 2013; 437(2): 164-171. 
Cartmell J, Schoepp DD. Regulation of neurotransmitter release by metabotropic glutamate receptors. J 
Neurochem 2000; 75(3): 889-907. 
Castanotto D, Rossi JJ. The promises and pitfalls of RNA-interference-based therapeutics. Nature 2009; 
457(7228): 426-433. 
!  27
Castren E, Voikar V, Rantamaki T. Role of neurotrophic factors in depression. Curr Opin Pharmacol 2007; 
7(1): 18-21. 
Catalanotto C, Cogoni C, Zardo G. MicroRNA in Control of Gene Expression: An Overview of Nuclear 
Functions. Int J Mol Sci 2016; 17(10). 
Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee SS. Therapeutic miRNA and siRNA: Moving from 
Bench to Clinic as Next Generation Medicine. Mol Ther Nucleic Acids 2017; 8: 132-143. 
Chen RJ, Kelly G, Sengupta A, Heydendael W, Nicholas B, Beltrami S et al. MicroRNAs as biomarkers of 
resilience or vulnerability to stress. Neuroscience 2015; 305: 36-48. 
Cheng LC, Pastrana E, Tavazoie M, Doetsch F. miR-124 regulates adult neurogenesis in the subventricular 
zone stem cell niche. Nat Neurosci 2009; 12(4): 399-408. 
Cirulli F, Francia N, Berry A, Aloe L, Alleva E, Suomi SJ. Early life stress as a risk factor for mental health: 
role of neurotrophins from rodents to non-human primates. Neurosci Biobehav Rev 2009; 33(4): 
573-585 
D'Sa C, Tolbert LM, Conti M, Duman RS. Regulation of cAMP-specific phosphodiesterases type 4B and 4D 
(PDE4) splice variants by cAMP signaling in primary cortical neurons. J Neurochem 2002; 81(4): 
745-757. 
Davis MJ, Haley T, Duvoisin RM, Raber J. Measures of anxiety, sensorimotor function, and memory in male 
and female mGluR4(-)/(-) mice. Behav Brain Res 2012; 229(1): 21-28. 
Davis MJ, Iancu OD, Acher FC, Stewart BM, Eiwaz MA, Duvoisin RM et al. Role of mGluR4 in acquisition 
of fear learning and memory. Neuropharmacology 2013; 66: 365-372. 
Dias C, Feng J, Sun H, Shao NY, Mazei-Robison MS, Damez-Werno D et al. beta-catenin mediates stress 
resilience through Dicer1/microRNA regulation. Nature 2014; 516(7529): 51-55. 
Dickson DA, Paulus JK, Mensah V, Lem J, Saavedra-Rodriguez L, Gentry A et al. Reduced levels of 
miRNAs 449 and 34 in sperm of mice and men exposed to early life stress. Transl Psychiatry 2018; 
8(1): 101. 
Duan DM, Dong X, Tu Y, Liu P. A microarray study of chronic unpredictable mild stress rat blood serum 
with electro-acupuncture intervention. Neurosci Lett 2016; 627: 160-167. 
Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 
59(12): 1116-1127. 
Ebert MS, Sharp PA. Roles for microRNAs in conferring robustness to biological processes. Cell 2012; 
149(3): 515-524. 
Enatescu VR, Papava I, Enatescu I, Antonescu M, Anghel A, Seclaman E et al. Circulating Plasma Micro 
RNAs in Patients with Major Depressive Disorder Treated with Antidepressants: A Pilot Study. 
Psychiatry Investig 2016; 13(5): 549-557. 
Fan HM, Sun XY, Guo W, Zhong AF, Niu W, Zhao L et al. Differential expression of microRNA in 
peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients. J 
Psychiatr Res 2014; 59: 45-52. 
Fiori LM, Lopez JP, Richard-Devantoy S, Berlim M, Chachamovich E, Jollant F et al. Investigation of 
miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response. Int J 
Neuropsychopharmacol 2017; 20(8): 619-623. 
Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of 
microRNAs. Genome Res 2009; 19(1): 92-105. 
!  28
Fryers T, Brugha T. Childhood determinants of adult psychiatric disorder. Clin Pract Epidemiol Ment Health 
2013; 9: 1-50. 
Ghahhari NM, Babashah S. Interplay between microRNAs and WNT/beta-catenin signalling pathway 
regulates epithelial-mesenchymal transition in cancer. Eur J Cancer 2015; 51(12): 1638-1649. 
Grieco SF, Velmeshev D, Magistri M, Eldar-Finkelman H, Faghihi MA, Jope RS et al. Ketamine up-
regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen 
synthase kinase-3. World J Biol Psychiatry 2017; 18(6): 445-456. 
Gururajan A, Naughton ME, Scott KA, O'Connor RM, Moloney G, Clarke G et al. MicroRNAs as 
biomarkers for major depression: a role for let-7b and let-7c. Transl Psychiatry 2016; 6(8): e862. 
Ha TY. MicroRNAs in Human Diseases: From Autoimmune Diseases to Skin, Psychiatric and 
Neurodegenerative Diseases. Immune Netw 2011; 11(5): 227-244. 
Haramati S, Navon I, Issler O, Ezra-Nevo G, Gil S, Zwang R et al. MicroRNA as repressors of stress-
induced anxiety: the case of amygdalar miR-34. J Neurosci 2011; 31(40): 14191-14203. 
He S, Liu X, Jiang K, Peng D, Hong W, Fang Y et al. Alterations of microRNA-124 expression in peripheral 
blood mononuclear cells in pre- and post-treatment patients with major depressive disorder. Journal of 
Psychiatric Research 2016; 78: 65-71. 
He Y, Zhou Y, Xi Q, Cui H, Luo T, Song H et al. Genetic variations in microRNA processing genes are 
associated with susceptibility in depression. DNA Cell Biol 2012; 31(9): 1499-1506. 
Higuchi F, Uchida S, Yamagata H, Abe-Higuchi N, Hobara T, Hara K et al. Hippocampal MicroRNA-124 
Enhances Chronic Stress Resilience in Mice. J Neurosci 2016; 36(27): 7253-7267. 
Holmes A, Singewald N. Individual differences in recovery from traumatic fear. Trends Neurosci 2013; 
36(1): 23-31. 
Ihara K, Yoshida H, Jones PB, Hashizume M, Suzuki Y, Ishijima H et al. Serum BDNF levels before and 
after the development of mood disorders: a case-control study in a population cohort. Transl 
Psychiatry 2016; 6: e782. 
Issler O, Haramati S, Paul ED, Maeno H, Navon I, Zwang R et al. MicroRNA 135 is essential for chronic 
stress resiliency, antidepressant efficacy, and intact serotonergic activity. Neuron 2014; 83(2): 344-360. 
Januar V, Saffery R, Ryan J. Epigenetics and depressive disorders: a review of current progress and future 
directions. Int J Epidemiol 2015; 44(4): 1364-1387. 
Jiang Y, Zhu J. Effects of sleep deprivation on behaviors and abnormal hippocampal BDNF/miR-10B 
expression in rats with chronic stress depression. Int J Clin Exp Pathol 2015; 8(1): 586-593. 
Jin J, Kim SN, Liu X, Zhang H, Zhang C, Seo JS et al. miR-17-92 Cluster Regulates Adult Hippocampal 
Neurogenesis, Anxiety, and Depression. Cell Rep 2016; 16(6): 1653-1663. 
Jope RS, Roh MS. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. 
Curr Drug Targets 2006; 7(11): 1421-1434. 
Juruena MF. Early-life stress and HPA axis trigger recurrent adulthood depression. Epilepsy Behav 2014; 38: 
148-159 
Juruena MF, Bocharova M, Agustini B, Young AH. Atypical depression and non-atypical depression: Is HPA 
axis function a biomarker? A systematic review. J Affect Disord 2018; 233: 45-67. 
Karatsoreos IN, McEwen BS. Resilience and vulnerability: a neurobiological perspective. F1000Prime Rep 
2013; 5: 13. 
!  29
Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM, Jr. et al. HPA axis in major 
depression: cortisol, clinical symptomatology and genetic variation predict cognition. Mol Psychiatry 
2017; 22(4): 527-536. 
Kennedy SH, Lam RW, McIntyre RS, Tourjman SV, Bhat V, Blier P et al. Canadian Network for Mood and 
Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major 
Depressive Disorder: Section 3. Pharmacological Treatments. Can J Psychiatry 2016; 61(9): 540-560. 
Klengel T, Binder EB. Epigenetics of Stress-Related Psychiatric Disorders and Gene x Environment 
Interactions. Neuron 2015; 86(6): 1343-1357. 
Kuang WH, Dong ZQ, Tian LT, Li J. MicroRNA-451a, microRNA-34a-5p, and microRNA-221-3p as 
predictors of response to antidepressant treatment. Braz J Med Biol Res 2018; 51(7): e7212. 
Larsen MH, Mikkelsen JD, Hay-Schmidt A, Sandi C. Regulation of brain-derived neurotrophic factor 
(BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant 
treatment. J Psychiatr Res 2010; 44(13): 808-816. 
Launay JM, Mouillet-Richard S, Baudry A, Pietri M, Kellermann O. Raphe-mediated signals control the 
hippocampal response to SRI antidepressants via miR-16. Transl Psychiatry 2011; 1: e56. 
Lee BH, Kim YK. The roles of BDNF in the pathophysiology of major depression and in antidepressant 
treatment. Psychiatry Investig 2010; 7(4): 231-235. 
Li J, Meng H, Cao W, Qiu T. MiR-335 is involved in major depression disorder and antidepressant treatment 
through targeting GRM4. Neurosci Lett 2015; 606: 167-172. 
Li YJ, Xu M, Gao ZH, Wang YQ, Yue Z, Zhang YX et al. Alterations of serum levels of BDNF-related 
miRNAs in patients with depression. PLoS One 2013; 8(5): e63648. 
Liang Y, Zhao G, Sun R, Mao Y, Li G, Chen X et al. Genetic variants in the promoters of let-7 family are 
associated with an increased risk of major depressive disorder. J Affect Disord 2015; 183: 295-299. 
Lim DH, Oh CT, Lee L, Hong JS, Noh SH, Hwang S et al. The endogenous siRNA pathway in Drosophila 
impacts stress resistance and lifespan by regulating metabolic homeostasis. FEBS Lett 2011; 585(19): 
3079-3085. 
Lin CC, Tsai MC, Lee CT, Sun MH, Huang TL. Antidepressant treatment increased serum miR-183 and 
miR-212 levels in patients with major depressive disorder. Psychiatry Res 2018; 270: 232-237. 
Lin PY, Tseng PT. Decreased glial cell line-derived neurotrophic factor levels in patients with depression: a 
meta-analytic study. J Psychiatr Res 2015; 63: 20-27. 
Liu BB, Luo L, Liu XL, Geng D, Liu Q, Yi LT. 7-Chlorokynurenic acid (7-CTKA) produces rapid 
antidepressant-like effects: through regulating hippocampal microRNA expressions involved in TrkB-
ERK/Akt signaling pathways in mice exposed to chronic unpredictable mild stress. 
Psychopharmacology (Berl) 2015; 232(3): 541-550. 
Liu BB, Luo L, Liu XL, Geng D, Liu Q, Yi LT. 7-Chlorokynurenic acid (7-CTKA) produces rapid 
antidepressant-like effects: through regulating hippocampal microRNA expressions involved in TrkB-
ERK/Akt signaling pathways in mice exposed to chronic unpredictable mild stress. 
Psychopharmacology (Berl) 2015; 232(3): 541-550. 
Liu Q, Sun NN, Wu ZZ, Fan DH, Cao MQ. Chaihu-Shugan-San exerts an antidepressive effect by 
downregulating miR-124 and releasing inhibition of the MAPK14 and Gria3 signaling pathways. 
Neural Regen Res 2018; 13(5): 837-845. 
Liu Y, Liu D, Xu J, Jiang H, Pan F. Early adolescent stress-induced changes in prefrontal cortex 
miRNA-135a and hippocampal miRNA-16 in male rats. Dev Psychobiol 2017; 59(8): 958-969. 
!  30
Lockhart S, Sawa A, Niwa M. Developmental trajectories of brain maturation and behavior: Relevance to 
major mental illnesses. J Pharmacol Sci 2018; 137(1): 1-4. 
Lopez JP, Lim R, Cruceanu C, Crapper L, Fasano C, Labonte B et al. miR-1202 is a primate-specific and 
brain-enriched microRNA involved in major depression and antidepressant treatment. Nat Med 2014; 
20(7): 764-768. 
Lopez JP, Pereira F, Richard-Devantoy S, Berlim M, Chachamovich E, Fiori LM et al. Co-Variation of 
Peripheral Levels of miR-1202 and Brain Activity and Connectivity During Antidepressant Treatment. 
Neuropsychopharmacology 2017; 42(10): 2043-2051. 
Lorsch ZS, Loh YE, Purushothaman I, Walker DM, Parise EM, Salery M et al. Estrogen receptor alpha 
drives pro-resilient transcription in mouse models of depression. Nat Commun 2018; 9(1): 1116. 
Ma K, Xu A, Cui S, Sun MR, Xue YC, Wang JH. Impaired GABA synthesis, uptake and release are 
associated with depression-like behaviors induced by chronic mild stress. Transl Psychiatry 2016; 
6(10): e910. 
Maffioletti E, Cattaneo A, Rosso G, Maina G, Maj C, Gennarelli M et al. Peripheral whole blood microRNA 
alterations in major depression and bipolar disorder. J Affect Disord 2016; 200: 250-258. 
Maffioletti E, Salvi A, Conde I, Maj C, Gennarelli M, De Petro G et al. Study of the in vitro modulation 
exerted by the antidepressant drug escitalopram on the expression of candidate microRNAs and their 
target genes. Mol Cell Neurosci 2017; 85: 220-225. 
Maffioletti E, Tardito D, Gennarelli M, Bocchio-Chiavetto L. Micro spies from the brain to the periphery: 
new clues from studies on microRNAs in neuropsychiatric disorders. Front Cell Neurosci 2014; 8: 75. 
Maheu M, Lopez JP, Crapper L, Davoli MA, Turecki G, Mechawar N. MicroRNA regulation of central glial 
cell line-derived neurotrophic factor (GDNF) signalling in depression. Transl Psychiatry 2015; 5: 
e511. 
McEwen BS. Brain on stress: how the social environment gets under the skin. Proc Natl Acad Sci U S A 
2012; 109 Suppl 2: 17180-17185. 
Menke A, Binder EB. Epigenetic alterations in depression and antidepressant treatment. Dialogues Clin 
Neurosci 2014; 16(3): 395-404. 
Miao N, Jin J, Kim SN, Sun T. Hippocampal MicroRNAs Respond to Administration of Antidepressant 
Fluoxetine in Adult Mice. Int J Mol Sci 2018; 19(3). 
Mora C, Zonca V, Riva MA, Cattaneo A. Blood biomarkers and treatment response in major depression. 
Expert Rev Mol Diagn 2018; 18(6): 513-529. 
Mori MA, Raghavan P, Thomou T, Boucher J, Robida-Stubbs S, Macotela Y et al. Role of microRNA 
processing in adipose tissue in stress defense and longevity. Cell Metab 2012; 16(3): 336-347. 
Mundalil Vasu M, Anitha A, Takahashi T, Thanseem I, Iwata K, Asakawa T et al. Fluoxetine Increases the 
Expression of miR-572 and miR-663a in Human Neuroblastoma Cell Lines. PLoS One 2016; 11(10): 
e0164425. 
Nakanishi K. Anatomy of RISC: how do small RNAs and chaperones activate Argonaute proteins? Wiley 
Interdiscip Rev RNA 2016; 7(5): 637-660. 
Nestler EJ, Pena CJ, Kundakovic M, Mitchell A, Akbarian S. Epigenetic Basis of Mental Illness. 
Neuroscientist 2016; 22(5): 447-463. 
O'Brien WT, Klein PS. Regulation of glycogen synthase kinase-3 in patients with affective disorders. Biol 
Psychiatry 2007; 61(2): 139-141. 
!  31
O'Connor RM, Grenham S, Dinan TG, Cryan JF. microRNAs as novel antidepressant targets: converging 
effects of ketamine and electroconvulsive shock therapy in the rat hippocampus. Int J 
Neuropsychopharmacol 2013; 16(8): 1885-1892. 
Oved K, Farberov L, Gilam A, Israel I, Haguel D, Gurwitz D et al. MicroRNA-Mediated Regulation of 
ITGB3 and CHL1 Is Implicated in SSRI Action. Front Mol Neurosci 2017; 10: 355. 
Oved K, Morag A, Pasmanik-Chor M, Oron-Karni V, Shomron N, Rehavi M et al. Genome-wide miRNA 
expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant 
response biomarkers. Pharmacogenomics 2012; 13(10): 1129-1139. 
Oved K, Morag A, Pasmanik-Chor M, Rehavi M, Shomron N, Gurwitz D. Genome-wide expression 
profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of 
antidepressants. Transl Psychiatry 2013; 3: e313. 
Pan B, Liu Y. Effects of duloxetine on microRNA expression profile in frontal lobe and hippocampus in a 
mouse model of depression. Int J Clin Exp Pathol 2015; 8(11): 15454-15461. 
Pearson-Leary J, Eacret D, Chen R, Takano H, Nicholas B, Bhatnagar S. Inflammation and vascular 
remodeling in the ventral hippocampus contributes to vulnerability to stress. Transl Psychiatry 2017; 
7(6): e1160. 
Peng L, Liu Z, Xiao J, Tu Y, Wan Z, Xiong H et al. MicroRNA-148a suppresses epithelial-mesenchymal 
transition and invasion of pancreatic cancer cells by targeting Wnt10b and inhibiting the Wnt/beta-
catenin signaling pathway. Oncol Rep 2017; 38(1): 301-308. 
Pfau ML, Russo SJ. Peripheral and Central Mechanisms of Stress Resilience. Neurobiol Stress 2015; 1: 
66-79. 
Pilc A, Chaki S, Nowak G, Witkin JM. Mood disorders: regulation by metabotropic glutamate receptors. 
Biochem Pharmacol 2008; 75(5): 997-1006. 
Rao P, Benito E, Fischer A. MicroRNAs as biomarkers for CNS disease. Front Mol Neurosci 2013; 6: 39. 
Rehfeld F, Rohde AM, Nguyen DT, Wulczyn FG. Lin28 and let-7: ancient milestones on the road from 
pluripotency to neurogenesis. Cell Tissue Res 2015; 359(1): 145-160. 
Roy B, Dunbar M, Shelton RC, Dwivedi Y. Identification of MicroRNA-124-3p as a Putative Epigenetic 
Signature of Major Depressive Disorder. Neuropsychopharmacology 2017; 42(4): 864-875. 
Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other 
diseases. Nat Rev Drug Discov 2017; 16(3): 203-222. 
Ryan KM, O'Donovan SM, McLoughlin DM. Electroconvulsive stimulation alters levels of BDNF-
associated microRNAs. Neurosci Lett 2013; 549: 125-129. 
Schmidt U, Herrmann L, Hagl K, Novak B, Huber C, Holsboer F et al. Therapeutic Action of Fluoxetine is 
Associated with a Reduction in Prefrontal Cortical miR-1971 Expression Levels in a Mouse Model of 
Posttraumatic Stress Disorder. Front Psychiatry 2013; 4: 66. 
Serafini G, Pompili M, Hansen KF, Obrietan K, Dwivedi Y, Shomron N et al. The involvement of 
microRNAs in major depression, suicidal behavior, and related disorders: a focus on miR-185 and 
miR-491-3p. Cell Mol Neurobiol 2014; 34(1): 17-30. 
Smalheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y. MicroRNA expression is down-
regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One 2012; 7(3): 
e33201. 
Song M-F, Dong J-Z, Wang Y-W, He J, Ju X, Zhang L et al. CSF miR-16 is decreased in major depression 
patients and its neutralization in rats induces depression-like behaviors via a serotonin transmitter 
system. Journal of Affective Disorders 2015; 178: 25-31. 
!  32
Syed SA, Nemeroff CB. Early Life Stress, Mood, and Anxiety Disorders. Chronic Stress (Thousand Oaks) 
2017; 1. 
Torres-Berrio A, Lopez JP, Bagot RC, Nouel D, Dal Bo G, Cuesta S et al. DCC Confers Susceptibility to 
Depression-like Behaviors in Humans and Mice and Is Regulated by miR-218. Biol Psychiatry 2017; 
81(4): 306-315. 
Tost H, Champagne FA, Meyer-Lindenberg A. Environmental influence in the brain, human welfare and 
mental health. Nat Neurosci 2015; 18(10): 1421-1431. 
Uchida S, Hara K, Kobayashi A, Otsuki K, Yamagata H, Hobara T et al. Epigenetic status of Gdnf in the 
ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron 2011; 69(2): 
359-372. 
Voleti B, Duman RS. The roles of neurotrophic factor and Wnt signaling in depression. Clin Pharmacol Ther 
2012; 91(2): 333-338. 
Volk N, Pape JC, Engel M, Zannas AS, Cattane N, Cattaneo A et al. Amygdalar MicroRNA-15a Is Essential 
for Coping with Chronic Stress. Cell Rep 2016; 17(7): 1882-1891. 
Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical 
trials. Biochim Biophys Acta 2010; 1803(11): 1231-1243. 
Wang X, Sundquist K, Hedelius A, Palmer K, Memon AA, Sundquist J. Circulating microRNA-144-5p is 
associated with depressive disorders. Clin Epigenetics 2015; 7: 69. 
Wingo AP, Almli LM, Stevens JS, Klengel T, Uddin M, Li Y et al. DICER1 and microRNA regulation in 
post-traumatic stress disorder with comorbid depression. Nat Commun 2015; 6: 10106. 
Wu G, Feder A, Cohen H, Kim JJ, Calderon S, Charney DS et al. Understanding resilience. Front Behav 
Neurosci 2013; 7. 
Xu B, Hsu PK, Karayiorgou M, Gogos JA. MicroRNA dysregulation in neuropsychiatric disorders and 
cognitive dysfunction. Neurobiol Dis 2012; 46(2): 291-301. 
Xu C, Yang C, Zhang A, Xu Y, Li X, Liu Z et al. The interaction of miR-34b/c polymorphisms and negative 
life events increases susceptibility to major depressive disorder in Han Chinese population. Neurosci 
Lett 2017; 651: 65-71. 
Xu J, Wang R, Liu Y, Liu D, Jiang H, Pan F. FKBP5 and specific microRNAs via glucocorticoid receptor in 
the basolateral amygdala involved in the susceptibility to depressive disorder in early adolescent 
stressed rats. J Psychiatr Res 2017; 95: 102-113. 
Yang X, Yang Q, Wang X, Luo C, Wan Y, Li J et al. MicroRNA expression profile and functional analysis 
reveal that miR-206 is a critical novel gene for the expression of BDNF induced by ketamine. 
Neuromolecular Med 2014; 16(3): 594-605. 
Yi LT, Li J, Liu BB, Luo L, Liu Q, Geng D. BDNF-ERK-CREB signalling mediates the role of miR-132 in 
the regulation of the effects of oleanolic acid in male mice. J Psychiatry Neurosci 2014; 39(5): 
348-359. 
Yu H, Fan C, Yang L, Yu S, Song Q, Wang P et al. Ginsenoside Rg1 Prevents Chronic Stress-Induced 
Depression-Like Behaviors and Neuronal Structural Plasticity in Rats. Cell Physiol Biochem 2018; 
48(6): 2470-2482. 
Zhang Y, Wang Y, Wang L, Bai M, Zhang X, Zhu X. Dopamine Receptor D2 and Associated microRNAs 
Are Involved in Stress Susceptibility and Resistance to Escitalopram Treatment. Int J 
Neuropsychopharmacol 2015; 18(8). 
!  33
Zhang Y, Zhu X, Bai M, Zhang L, Xue L, Yi J. Maternal deprivation enhances behavioral vulnerability to 
stress associated with miR-504 expression in nucleus accumbens of rats. PLoS One 2013; 8(7): 
e69934. 
Zurawek D, Kusmider M, Faron-Gorecka A, Gruca P, Pabian P, Kolasa M et al. Time-dependent miR-16 
serum fluctuations together with reciprocal changes in the expression level of miR-16 in mesocortical 
circuit contribute to stress resilient phenotype in chronic mild stress - An animal model of depression. 
Eur Neuropsychopharmacol 2016; 26(1): 23-36. 
!  34
